The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Adult
Aged
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ metabolism
Carcinoma, Ductal, Breast
/ metabolism
Carcinoma, Intraductal, Noninfiltrating
Female
Humans
Immunohistochemistry
Ki-67 Antigen
/ metabolism
Middle Aged
Receptor, Transforming Growth Factor-beta Type I
/ analysis
Receptors, Estrogen
/ metabolism
Ki67
breast cancer
estrogen receptor
transforming growth factor beta receptor 1
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
06
08
2019
accepted:
04
02
2020
pubmed:
28
2
2020
medline:
18
5
2021
entrez:
28
2
2020
Statut:
ppublish
Résumé
Most breast cancers are derived from the luminal epithelium, which composes the inside of the breast ductal structure. Ductal carcinoma in situ (DCIS) leads to invasive ductal carcinoma, but noncancerous intraductal proliferative lesions are also a risk factor for ductal carcinoma. The transforming growth factor beta (TGFB) signaling pathway behaves as a tumor suppressor in the early stage of cancer, and conversely as a tumor growth factor in invasive stages in several cancers. In this study, we performed immunohistochemistry with an antibody that detects the cytoplasmic region of TGFB receptor 1 (TGFBR1) and elucidated TGFBR1 protein expression in luminal epithelial cells of noncancerous breast ducts and in several cases of DCIS and invasive carcinoma. TGFBR1 expression was higher in noncancerous breast tissue than in cancerous tissue, and a difference in expression was also seen among histological subtypes. Comparing the expression level of TGFBR1 in cancer cells and clinico-pathological parameters, cases expressing low TGFBR1 tended to show low estrogen receptor expression, large tumor size (≥10 mm), and a high Ki67 labeling index. These data suggested that TGFBR1 protein expression may be related to the suppression of breast cancer cell growth.
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
MKI67 protein, human
0
Receptors, Estrogen
0
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
TGFBR1 protein, human
EC 2.7.11.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-339Subventions
Organisme : Smoking Research Foundation
Organisme : JSPS KAKENHI
ID : 16K07165
Organisme : JSPS KAKENHI
ID : 16K08687
Organisme : JSPS KAKENHI
ID : 17K08727
Organisme : The Hokkoku Cancer Foundation
Informations de copyright
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Black MM, Barclay TH, Cutler SJ, Hankey BF, Asire AJ. Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 1972; 29: 338-43.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-51.
Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
Massagué J. TGFbeta in cancer. Cell 2008; 134: 215-30.
Pasche B, Luo Y, Rao PH et al. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 1998; 58: 2727-32.
Pasche B, Kolachana P, Nafa K et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59: 5678-82.
Kaklamani VG, Hou N, Bian Y et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003; 21: 3236-43.
Liao RY, Mao C, Qiu LX, Ding H, Chen Q, Pan HF. TGFBR1*6A/9A polymorphism and cancer risk: A meta-analysis of 13,662 cases and 14,147 controls. Mol Biol Rep 2010; 37: 3227-32.
Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 2008; 68: 1319-28.
Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998; 58: 4805-10.
Tian F, Byfield SD, Parks WT et al. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2004; 64: 4523-30.
Hachim IY, Hachim MY, López-Ozuna VM, Ali S, Lebrun JJ. A dual prognostic role for the TGFβ receptors in human breast cancer. Hum Pathol 2016; 57: 140-51.
Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer, The 18th Edition. Kanehara & Co. Ltd, 2018.
Nakamura R, Oyama T, Tajiri R et al. Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma. Cancer Sci 2015; 106: 656-64.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
Curigliano G, Burstein HJ, Winer EP et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-712.
R Core Team. R: A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing, 2019. https://www.R-project.org/. Accessed December 27, 2019.
Docea AO, Mitruţ P, Grigore D, Pirici D, Călina DC, Gofiţă E. Immunohistochemical expression of TGF beta (TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Rom J Morphol Embryol 2012; 53: 683-92.
Moore-Smith L, Pasche B. TGFBR1 signaling and breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 89-95.
Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100: 8430-35.
Band AM, Laiho M. Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 109-115.
Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH. Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 2005; 167: 409-417.
Subik K, Lee JF, Baxter L et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 2010; 4: 35-41.
Jiang G, Zhang S, Yazdanparast A et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 2016; 17: 525.
Zhang B, Wang J, Wang X et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014; 513: 382-87.
Gry M, Rimini R, Strömberg S et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 2009; 10: 365.